Milestone Pharmaceuticals Inc. - MIST Forward P/S Multiple

Official company branding of Milestone Pharmaceuticals Inc (MIST)

Milestone Pharmaceuticals (MIST) is pursuing expansion in the US cardiology market through the introduction of etripamil. The company is currently in an investment plateau phase characterized by high pre-marketing expenses. P/S expectations reflect a valuation trend where 34.50 serves as the target level. Financial stability relies on reserves and investor capital, as the clinical trial stage precludes current sales.

MIST (Milestone Pharmaceuticals Inc.) Forward Price to Sales history from 07/04/2022 to 11/13/2026

Comprehensive metric breakdowns and analytics for Milestone Pharmaceuticals Inc (MIST)

- market price and analyst price targets:
Price Chart Milestone Pharmaceuticals Inc.|MIST - Broker Consensus Forecast
- issuer market value details:
Market Capitalization Milestone Pharmaceuticals Inc|MIST - Total Enterprise Value
- issuer book value statistics:
Accounting Value per Share Milestone Pharmaceuticals|MIST - Accounting Value of Company|Market Value to Book Value Ratio milestonepharma.com|MIST - Total Asset Value of Company
- debt and liquidity data:
Total Debt to Capital Milestone Pharmaceuticals|MIST - Long-Term Debt to Capital Coefficient|Short-Term Debt to Capital Milestone Pharmaceuticals|MIST - Company Aggregate Debts|Debt to Book Capitalization Ratio Milestone Pharmaceuticals Inc|MIST - Company Long-Term Loans and Borrowings|Company Short-Term Debt Milestone Pharmaceuticals|Quick Ratio milestonepharma.com
- net income and valuation multiples indicators:
MIST - Net Profit|Projected Future Earnings Milestone Pharmaceuticals|MIST - Price to Earnings Ratio|Forward P/E Multiple Milestone Pharma|MIST - Price to Earnings Adjusted for Growth Rate|Enterprise Value to EBITDA Ratio Milestone Pharmaceuticals Inc|MIST - Operating profit EBITDA|Net earnings per share for the last 12 months Milestone Pharmaceuticals|MIST - Earnings per share for the last four quarters|Quarterly EPS earnings growth milestonepharma.com|MIST - Expected net earnings per share growth this year|Earnings growth forecast for next year Milestone Pharmaceuticals
- company sales and revenue statistics:
MIST - Company Sales|Projected Sales Volume Milestone Pharmaceuticals Inc.|MIST - P/S Multiple|Price-to-Projected Revenue Ratio Milestone Pharmaceuticals Inc
Fundamental company analysis:MIST (Milestone Pharmaceuticals Inc.)
Product sample of Milestone Pharmaceuticals Inc

The high scalability of global sales for Milestone Pharmaceuticals (MIST) nasal sprays, coupled with low production costs, makes the company sensitive to revenue expectations. By analyzing the forward P/S multiple on the GURU.Markets platform, an investor can observe the ratio of market capitalization to expected sales volume, which allows for an assessment of the asset's overvaluation relative to future cash flows and actual capital inflows.

Key competitors

Price-to-Projected Revenue Ratio Regeneron REGN|IRTC: Market Cap to Projected Revenue|Lantheus Medical Imaging - Forward P/S Multiple|Market Cap to Future Revenue Ratio Mineralys Corp|HTFL (heartflow.com) - Forward Price-to-Revenue Multiple|kestramedical.com - Forward Price to Sales|Price-to-Projected Revenue Ratio Esperion|Amarin Corporation - Future Price to Revenue|Forward P/S Multiple AVR|TNYA (tenayatherapeutics.com) - Forward Price to Sales|Forward P/S Multiple CVRX (CVRx, Inc.)|Forward P/S Multiple Cardiol Therapeutics Inc CRDL|BEAT - Price-to-Projected Revenue Ratio|Forward Price to Sales TENX (Tenax Therapeutics Inc.)|Adagio Medical Holdings Inc. (ADGM) - Price-to-Projected Revenue Ratio|Forward Price-to-Revenue Multiple BioCardia Inc|VTAK (Catheter Precision) - Forward P/S Multiple|Forward P/S Multiple ARCA Bio|Forward P/S Multiple ACST|Forward Price-to-Revenue Multiple Aerovate Therapeutics Inc. AVTE|Forward P/S Multiple VERV (Verve Therapeutics, Inc.)|Windtree Therapeutics Inc. (WINT) - Market Cap to Future Revenue Ratio